- August 12-17, 2018
Alethia Biotherapeutics to present at the 18th International Biotechnology Symposium and Exposition at le Palais des Congrès in Montreal, Canada. Dr. Mario Filion will present: “Targeting EMT to treat advanced carcinomas with an anti-clusterin antibody”.
- April 1 – 5, 2017
Alethia Biotherapeutics to present at the Annual AACR Meeting at Walter E. Washington Convention Center, Washington, D.C., USA. Dr. Mario Filion and Dr. Julie Laurin will present: “Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies”.
Poster presentation CT098, April 4 2017, 8:00 AM – 12:00 PM, section 33, Session PO.CT03 – Phase I Clinical Trials
- April 16 – 20, 2016
Alethia Biotherapeutics to present at the Annual AACR Meeting at the Ernest N. Morial Convention Center, New Orleans, Louisiana, USA. Drs. Mario Filion and Gilles Tremblay will present: “Inhibition of Siglec-15 prevents bone loss in a mouse model of multiple myeloma”.
Poster presentation LB-091, April 18 2016, 8:00 AM – 12:00 PM, section 10, immunology session.
- October 9 – 12, 2015
Alethia Biotherapeutics to present at the Annual ASBMR Meeting at the Washington State Convention Center, Seattle, USA. Drs. Matthew Stuible and Gilles Tremblay will present data on the roles of Siglec-15 in osteoclasts:
The subcellular distribution of Siglec-15 in bone-resorbing osteoclasts implies complementary roles at the cell surface and ruffled border. Poster presentation #MO0220, October 12.
- October 26 – 29, 2014
Alethia Biotherapeutics to be part of the World ADC San Diego 2014.
Dr. Gilles Tremblay will be in attendance.
- October 8 – 9, 2014
Alethia Biotherapeutics to present at the 12th Annual Discovery on Target conference at the Westin Boston Waterfront, Boston, MA. Dr. Mario Filion, Chief Scientific Officer, will be a speaker during the Antibodies Against Membrane Protein Targets session on October 9: “Targeting Siglec-15 for Therapeutic Inhibition of Osteoclastic Bone Resorption Results in the Maintenance of Bone Formation”.
- September 12 – 15, 2014
Alethia Biotherapeutics to be part of the ASBMR Annual Meeting at the George R. Brown Convention Center, Houton, Texas.
Drs. Anna Moriatis and Gilles Tremblay will be in attendance.
- May 30 – June 3, 2014
Alethia Biotherapeutics to be part of the ASCO Annual Meeting at the McCormick Place, Chicago, Illinois.
Drs. Mario Filion and Gilles Tremblay will be in attendance.
- April 5 – 9, 2014
Alethia Biotherapeutics to present at the AACR Annual Meeting 2014 at the San Diego Convention Center, San Diego, California. Drs. Mario Filion and Gilles Tremblay will present data on:
AB-3A4: A novel KAAG1-targeting antibody-drug conjugate is active in models of ovarian carcinoma, triple-negative breast cancer and castration-resistant prostate cancer. Abstract #666. Sunday, Apr 06, 2014, 1:00 PM – 5:00 PM; Hall A-E, Poster Section 28
- January 13 -16, 2014
Alethia Biotherapeutics to be part of the Biotech Showcase 2014, Parc 55 Windham Hotel, San Francisco, USA. Yves Cornellier and Mario Filion will be in attendance.